natgillin/translations-raw huggingface dataset:
The process of any of the previous claims, wherein the calcium carbonate has a particle size from 0.1 to 100 µm, from 0.5 to 50 µm, from 1 to 15 µm, preferably from 2 to 10 µm, most preferably 3 to 5 µm. 
Postupak prema bilo kojem od prethodnih zahtjeva, pri čemu kalcij karbonat ima veličinu čestica od 0.5 do 50 µm, od 1 do 15 µm, poželjno od 2 do 10 µm, najpoželjnije 3 do 5 µm.
a third soluble TNF family cytokine domain, wherein the fusion polypeptide is substantially non-aggregating, wherein the soluble TNF family cytokine domain is selected from soluble TRAIL domains. 
treću topljivu citokinsku domenu iz TNF obitelji, pri čemu se fuzijski polipeptid znatno ne agregira i pri čemu je topljiva citokinska domena iz TNF obitelji izabrana od topljivih TRAIL domena.
The polypeptide of any one of claims 1-2 wherein at least one of the soluble TNF-family cytokine domains, particularly at least one of the soluble TNF family cytokine domains (iii) and (v) is a soluble TRAIL domain with an N-terminal sequence which starts between amino acid GIn120 and Val122 of human TRAIL and wherein Arg121 may be replaced by a neutral amino acid, e.g. Ser or Gly. 
Polipeptid prema bilo kojem od zahtjeva 1-2 pri kojem je najmanje jedna od topljivih citokinskih domena iz TNF obitelji, naročito najmanje jedna topljiva citokinska domena TNF obitelji (iii) i (v), topljiva TRAIL domena s N-terminalnim slijedom koji počinje između amino kiseline Gln120 i Val122 od humane TRAIL i pri čemu Arg121 može biti zamijenjena neutralnom aminokiselinom, primjerice Ser ili Gly.
The polypeptide of claim 3, wherein at least one of the soluble TNF family cytokine domains, particularly at least one of the soluble TNF family cytokine domains (iii) and (v) is a soluble TRAIL domain with an N-terminal sequence selected from 
Polipeptid iz zahtjeva 3 pri kojem je najmanje jedna topljiva citokinska domena iz TNF obitelji, naročito najmanje jedna topljiva citokinska domena TNF obitelji (iii) i (v), topljiva TRAIL domena s N-terminalnim slijedom izabranim između:
A compound selected from the Formula and salts thereof, wherein: 
Spoj izabran prema Formuli [image] i njegove soli, gdje:
R8, R9 and R10 are independently H, C1-C6 alkyl, or saturated or partially unsaturated C1-C6 heterocyclyl, wherein said alkyl and heterocyclyl are optionally substituted with one or more groups independently selected from C1-C6 alkyl, saturated or partially unsaturated C1-C6 heterocyclyl, ORa, NRaRb, C(=O)ORa and C(=O)NRaRb, or R8 and R9 together with the atoms to which they are attached form a saturated or partially unsaturated heterocyclic ring; 
, R9 i R10 su nezavisno H, C1-C6 alkil, ili zasićeni ili djelomično nezasićeni C1-C6 heterociklil, gdje su taj alkil i heterociklil po izboru supstituirani jednom ili više skupina koje se nezavisno biraju između C1-C6 alkil, zasićeni ili djelomično nezasićeni C1-C6 heterociklil, ORa, NRaRb, C(=O)ORa i C(=O)NRaRb, ili R8 i R9 zajedno s atomima za koje su spojeni formiraju zasićeni ili djelomično nezasićeni heterociklički prsten;
or R9 and R10 together with the atoms to which they are attached form a saturated or partially unsaturated heterocyclic ring; 
ili R9 i R10 zajedno s atomima za koje su spojeni formiraju zasićeni ili djelomično nezasićeni heterociklički prsten;
or R12 and R13 together with the atoms to which they are attached form a heteroaryl ring; 
ili R12 i R13 zajedno s atomima za koje su spojeni formiraju heteroarilni prsten;
a 5-6 membered heteroaryl ring having 1-2 nitrogen atoms; 
5-6-eročlani heteroarilni prsten s 1-2 atoma dušika;
SR6 wherein R6 is Vn-heteroaryl, n is 0, and the heteroaryl group is a 9-10 membered bicyclic heteroaromatic ring having 2-3 atoms independently selected from N, S and O, and optionally substituted with one or two groups independently selected from I, Br, C1-C6 alkyl and CO2H; 
SR6 gdje R6 je Vn-heteroaril, n je 0, i heteroarilna skupina je 9-10-eročlani biciklički heteroaromatski prsten s 2-3 atoma nezavisno izabrana između N, S i O, i po izboru supstituiran s jednom ili dvije skupine nezavisno izabrane između I, Br, C1-C6 alkil i CO2H;
(xiii) phenyl optionally substituted with Cl; 
(xiii) fenil po izboru supstituiran s Cl;
The use of a compound according to any of claims 1-16 in the manufacture of a medicament for the treatment of insulin dependent diabetes or non-insulin dependent diabetes mellitus. 
Uporaba spoja prema bilo kojem od zahtjeva 1-16 u proizvodnji lijeka za liječenje dijabetesa ovisnog o inzulinu ili dijabetesa melitusa koji nije ovisan o inzulinu.
A process for remineralization of water comprising the steps of: 
Postupak za remineralizaciju vode koji sadrži korake:
The process of claim 1, wherein the feed water is desalinated seawater, brackish water, brine, treated wastewater, natural water, ground water, surface water or rainfall. 
Postupak prema bilo kojem od prethodnih zahtjeva, pri čemu je ulazna voda desalinirana morska voda, boćata voda ili rasol, obrađena otpadna voda ili prirodna voda poput podzemne vode, površinske vode ili kišnice.
Compounds according to claims 1 to 6 for use in the treatment of transient cerebral ischemia, damages caused by ischemia and reperfusion, bullous pemphigo, rheumatoid arthritis, idiopathic fibrosis and glomerulonephritis. 
Spojevi u skladu sa zahtjevom 7 ili 8 za uporabu u terapiji prolazne cerebralne ishemije, oštećenja prouzročenih ishemijom i reperfuzijom, buloznog pemfigoida, reumatoidnog artritisa, idiopatske fibroze i glomerulonefritisa.
Modular semi-submersible structure, comprising a platform for boarding tourism, residential, commercial, industrial or military structures in the vicinity of coasts or in lake or river waters as well as in unprotected, off-coast areas, comprising two or more semi-submersible modules (10, 10', 10") connected to each other, each module (10) comprising: 
Modularna polu-uronjiva struktura, koji obuhvaća platformu za ukrcajni turizam, stambene, poslovne, industrijske i vojne strukture u blizini obale ili na jezerskim ili na riječnim vodama, te u nezaštićenim priobalnim područjima, koja sadrži dva ili više polu-uronjiva modula (10, 10 ', 10'') međusobno povezanih, pri čemu svaki modul (10) sadrži:
a hull (12), which is positioned under the deck, is provided internally with first watertight compartments having a ballast function and in conditions of use is submerged; and 
trup (12), koji se nalazi ispod palube, koji u unutrašnjosti ima prve vodonepropusne odjeljke koji imaju funkciju balasta i u uvjetima korištenja je uronjen; i
Semi-submersible structure according to claim 3, wherein the deck (11) has a box-like structure comprising at least two sheet-shaped elements, upper and lower, placed one above the other, and a plurality of interconnection beams positioned between the two sheet-shaped elements, the decks of two adjacent modules being structurally connected to each other at the respective sheet-shaped elements and at the interconnection beams. 
Polu-uronjiva struktura prema zahtjevu 3, naznačena time da paluba (11) ima strukturu sanduka koji sadrži najmanje dva elementa pločastog oblika, gornji i donji, postavljeni jedan iznad drugoga, i više greda za međusobno povezivanje koje se nalaze između dva elementa pločastog oblika, gdje su palube od dva susjedna modula strukturno međusobno spojene na odgovarajućim elementima pločastog oblika kod greda za međusobno povezivanje.
Semi-submersible structure according to claim 5, wherein the deck of each module has a regular polygonal-shaped perimeter and said right-angled grid passes through the corners of the polygonal perimeter, the modules being positioned in relation to one another with the respective interconnection beams connected to each other at the corners of the polygonal perimeter of the decks to form a single right-angled grid. 
Polu-uronjiva struktura prema zahtjevu 5, naznačena time da paluba svakog modula ima pravilni poligonalni oblik oboda i navedena pravokutna mreža prolazi kroz kutove oboda poligona, pri čemu su moduli smješteni jedan u odnosu na drugi i međusobno spojeni pomoću odgovarajućih greda za međusobno povezivanje na kutovima oboda poligona palube te oblikuju jednu pravokutnu rešetku.
Semi-submersible structure according to claim 9, wherein the hull (12) has smaller plan dimensions than the deck (11). 
Polu-uronjiva struktura prema zahtjevu 9, naznačena time da trup (12) ima manje tlocrtne dimenzije od palube (11).
Semi-submersible structure according to one or more of the previous claims, wherein each module comprises a ballasting system with water of the first and of the second watertight compartments, said system being utilisable to vary the level of water filling such watertight compartments and therefore to vary the waterline of the module (10, 10', 10"). 
Polu-uronjiva struktura prema jednom ili više prethodnih patentnih zahtjeva, naznačena time da svaki modul sadrži balastni sustav s vodom prvih i drugih vodonepropusnih odjeljaka, pri čemu navedeni sustav se može koristiti na način da se mijenja nivo vode kojom se pune odjeljci i time mijenja vodna linija modula (10, 10 ', 10 ").
Semi-submersible structure according to claim 12, wherein said ballasting system comprises one or more pumps for moving the water and a network of pumping pipes connected to said first and second watertight compartments (14, 15), the semi-submersible structure (1) having a centralised control system which controls the ballasting systems of the individual modules to ensure balanced filling and emptying of the watertight compartments of the modules and therefore balanced floating of the semi-submersible structure (1). 
Polu-uronjiva struktura prema zahtjevu 12, naznačen time da navedeni balastni sustav sadrži jednu ili više pumpi za pokretanje vode i mrežu cijevi za pumpanje je spojenih sa spomenutim prvim i drugim vodonepropusnim odjeljcima (14, 15), pri čemu polu-uronjiva struktura (1) ima centralizirani sustav kontrole koji kontrolira balastne sustave pojedinih modula kako bi se osiguralo uravnoteženo punjenje i pražnjenje vodonepropusnih odjeljaka od modula i stoga uravnoteženo plutanje u polu-uronjive strukture (1).
Semi-submersible structure according to claim 14, wherein said mooring system comprises one or more mooring lines, each mooring line having a guide pipe, which is positioned inside a connection column (13) and traverses the hull (12), and a movement apparatus. 
Polu-uronjiva struktura prema zahtjevu 14, naznačen time da navedeni sustav za privez sadrži jednu ili više linija za privez, pri čemu svaka linija za privez ima cijev za vođenje koja se nalazi unutar priključnog stupca (13) i prolazi kroz trup (12) i aparati za povlačenje.
Semi-submersible structure according to one or more of the previous claims, comprising one or more propulsion units, fixed or detachable, to move the structure in water. 
Polu-uronjiva struktura prema jednom ili više prethodnih patentnih zahtjeva, naznačena time da sadrži jednu ili više pogonskih jedinica, fiksne ili odvojive, za pomicanje strukturu na vodi.
positioning the semi-submersible modules already launched, with the columns substantially emerged, alongside each other at the relative decks; 
postavljanje polu-uronjivih modula koji su već porinuti, sa izronjenim stupcima, jednih pored drugih u odnosu na odgovarajuće palube;
and pharmaceutically acceptable salts thereof for use as medicaments. 
i njihove farmaceutski prihvatljive soli za uporabu kao lijekova.
for use as medicaments. 
za uporabu kao lijekova.
Compounds according to claims 7 or 8 for use in the treatment of transient cerebral ischemia, damages caused by ischemia and reperfusion, bullous pemphigo, rheumatoid arthritis, idiopathic fibrosis and glomerulonephritis. 
Spojevi u skladu sa zahtjevom 7 ili 8 za uporabu u terapiji prolazne cerebralne ishemije, oštećenja prouzročenih ishemijom i reperfuzijom, buloznog pemfigoida, reumatoidnog artritisa, idiopatske fibroze i glomerulonefritisa.
Pharmaceutical composition comprising a compound according to claims 7 or 8 in admixture with a suitable carrier thereof. 
Farmaceutski pripravak koji sadrži spoj u skladu sa zahtjevom 7 ili 8 u mješavini s prigodnim nosačem.
Process for the preparation of compounds of claims 1 to 6 comprising the step of: 
Proces pripreme spojeva iz zahtjeva 1 do 6 koji sadrži korake:
subsequent hydrolysis to carboxylic acids of formula (I) wherein X is OH, reaction with sulfonamides or amines to afford compounds of formula (I) wherein X is NHR3 where R3 is as defined in claim 1. 
naknadne hidrolize u karboksilne kiseline iz formule (I) gdje je X – OH, reakcije sa sulfonamidina ili aminima za dobivanje spojeva formule (I) gdje je X –NHR3, pri čemu je R3 definiran u zahtjevu 1.
A compound of formula (I), or a pharmaceutically acceptable salt, solvate or tautomer thereof, as claimed in any preceding claim, wherein the C ring, at the atom where it attaches to X, or directly to ring B if X is absent, is not further substituted except that such an atom may be substituted by hydrogen if chemically possible 
Spoj formule (I), ili njegova farmaceutski prihvatljiva sol, solvat ili tautomer, u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što prsten C, na atomu preko kojeg je vezan na X, ili izravno na prsten B ako je X odsutan, nije dodatno supstituiran, s tim što takav atom može biti supstituiran s vodikom ako je to kemijski izvedivo.
A compound of formula (I), or a pharmaceutically acceptable salt, solvate or tautomer thereof, as claimed in any of claims 1 to 10, that is 4-[2-(5-amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide. 
Spoj formule (I), ili njegova farmaceutski prihvatljiva sol, solvat ili tautomer, u skladu s bilo kojim od patentnih zahtjeva 1 do 10, naznačen time što je 4-[2-(5-amino-1H-pirazol-4-il)-4-klorfenoksi]-5-klor-2-fluor-N-1,3-tiazol-4-ilbenzensulfonamid.
with the proviso that the compound of formula (I) is not the following specific compound: 
uz uvjet da spoj formule (I) nije sljedeći specifični spoj: [image] .
(b1) a vinyl aromatic monomer, (b2) a carboxy containing compound, (b3) an acrylic compound selected from the group consisting of Isobutyl acrylate, isopentyl acrylate, pentyl acrylate, N-isopropyl acrylamide and butyl acrylate, preferably butyl acrylate; 
Dobivanje ter-kopolimera, od (b1) vinil aromatskih monomera, (b2) karboksi spoja, (b3) akrilnog spoja, izdvojenog iz grupe, koju čine izobutil akrilat, izopentil akrilat, pentil akrilat, N-izopropil akrilamid i butil akrilat, prvenstveno butil akrilat;
The process according to claim 1, wherein the partly acetalized polyhydroxy polymer has an acetalizing degree of 18-22% and is obtained by the reaction of acetalising the polyhydroxy polymer with an aldehyde. 
Postupak prema zahtjevu 1, naznačen time, da djelomično acetalirani poli- hidroksi polimer, ima stupanj acetaliranosti od 18-22%, te je dobiven reakcijom acetaliranja poli-hidroksi polimera s aldehidom.
A curable binder for impregnating mineral fibers, characterized in that it comprises 
Učvršćujuće vezivo za impregniranje mineralnih vlakana, naznačeno time, da sadrži
(b1) a vinyl aromatic monomer, (b2) a carboxy containing compound, (b3) an acrylic compound selected from the group consisting of isobutyl acrylate, isopentyl acrylate, pentyl acrylate, N-isopropyl acrylamide butyl acrylate, preferably butyl acrylate, preferably functionalized by the reaction with hydroxyl groups compounds, such as polyols or hydroxylamines; 
do 100 dijelova koji su po težini ter-kopolimera od (b1) vinil aromatskog monomera, (b2) karboksi spoja, (b3) akrilnog spoja, izdvojenog iz skupine koja se sastoji od izobutil- akrilata, izopentil akrilata, pentil akrilata, N-izopropil-akrilamid- butil akrilata, posebice butil akrilata, po mogućnosti dobijenog reakcijom s hidroksilnom skupinom spojeva, kao što su polioli ili hidroksi-lamina;
and from 1 to 3% by weight, related to a solid matter content, of plasticizing agent and/or up to maximum 1%, related to the solid matter content, stabilizer, wherein said curable binder is in the form of an aqueous solution. 
i od 1 do 3% težine, u odnosu na sadržaj krute tvari kod sredstva za plastificiranje i / ili do maksimalno 1%, u odnosu na sadržaj krute tvari, stabilizator, pri čemu je navedeno učvršćujuće vezivo u obliku vodene otopine.
The curable binder according to claims 10 - 12, further comprising flame retardancy additives are selected from the group consisting of urea, melamine, dicyandiamide, sodium carbonate, boric acid salts, antimony-containing compounds and derivatives of these, and water release agents, preferably aluminium oxide, trihydrate or magnesium hydroxide and optionally up to 1% nano titanium dioxide. 
Učvršćujuće vezivo, u skladu s patentnim zahtjevima 10 - 12, naznačeno time, da nadalje obuhvaća zagrijavanje plamena, kojem se dodaju aditivi izabrani iz skupine, koja se sastoji od uree, melamina, dicijan-diamida, natrij-karbonata, soli borne kiseline, spojeva koji sadržavaju antimon i derivate istih, i sredstva koja oslobađaju vodu, po mogućnosti aluminijev oksid, trihidrat ili magnezijev hidroksid, te prema izboru do 1% nano titan dioksida.
The method of claim 1, wherein the final predicted value of the current coding unit is obtained by using a weighted average of the obtained first predicted value and the obtained second predicted value. 
Uređaj iz Zahtjeva 1, gdje je druga predviđena vrijednost trenutne jedinice predviđanja dobivena pomoću uteženog prosjeka dobivene prve predviđene vrijednosti i najmanje jednog susjednog piksela ovisno o veličini koju treba predvidjeti trenutnom jedinicom predviđanja.
Use of one or more amino acid sequences comprising the sequence D/E- X- N-Z-S/T, wherein X and Z can be any natural amino acid except proline, for modifying a protein such that the protein is capable of being N-glycosylated by an oligosaccharyl transferase from Campylobacter spp. 
Uporaba jedne ili više sekvenci aminokiselina koje sadrže sekvencu D/E- X- N-Z-S/T, gdje X i Z mogu biti bilo koja prirodna aminokiselina osim prolina, za modificiranje proteina tako da oligosaharil transferaza iz Campylobacter spp. može taj protein N-glikozilirati.
Use according to claim 1, wherein the protein is modified by addition, deletion and/or substitution of one or more amino acids in said protein. 
Uporaba prema zahtjevu 1, gdje se protein modificira dodavanjem, brisanjem i/ili zamjenom jedne ili više aminokiselina u tom proteinu.
a frame (10) which is rotatable about a horizontal hinge axis (H), and 
okvir (10) koji se može rotirati oko osi horizontalnih šarki (H), i
A pharmaceutical composition for use in a method of therapy, comprising one or more components selected from the group consisting of: 
Farmaceutska kompozicija za primjenu u terapeutskoj metodi, koja sadrži jednu ili više komponenti izabranih iz grupe koja se sastoji od:
The pharmaceutical composition for use as claimed in claim 1, wherein the method of therapy is a method of treatment or prevention of a cancer characterized by expression of the tumor-associated antigen according to claim 1, in which the cancer is an esophageal tumor, an ovarian tumor, a head-neck tumor, a kidney tumor, a liver tumor, a lung tumor, a breast tumor, a prostate tumor, a colon tumor, a gastric tumor, a stomach cancer, a pancreatic tumor, a renal cell carcinoma, a colon carcinoma or a mammary carcinoma. 
Farmaceutska kompozicija za primjenu prema zahtjevu 1, gdje je terapeutska metoda metoda liječenja ili prevencije raka, naznačeno time da je ekspresija antigena povezanog s tumorom prema zahtjevu 1, pri čemu je rak tumor jednjaka, tumor jajnika, tumor glave-vrata, tumor bubrega, tumor jetre, tumor pluća, tumor dojke, tumor prostate, tumor kolona, tumor želuca, rak želuca, tumor pankreasa, karcinom bubrežnih ćelija, karcinom kolona ili karcinom mliječnih žlijezda.
A pharmaceutical composition, comprising one or more components selected from the group consisting of: a tumor-associated antigen or a part thereof, 
Farmaceutska kompozicija za primjenu u terapeutskoj metodi, koja sadrži jednu ili više komponenti izabranih iz grupe koja se sastoji od:
The method according to claim 1, wherein the precipitation of calcium carbonate coming out from said softening unit (S) or entering said crystallization - evaporation unit (EC)is controlled by acidic treatment. 
Postupak prema zahtjevu 1, naznačen time, da se taloženje kalcijevog karbonata koji izlazi iz navedene jedinice za omekšavanje (S) ili ulazi u navedenu jedinicu za kristalizaciju isparavanje (EC) kontrolira obradom s kiselinom.
The method according to claim 1, wherein the precipitation of calcium sulphate In the liquid stream fed to the flue gas treatment unit is controlled by reducing the flow rate of said fraction of liquid effluent coming from the waste treatment unit (TSD) to said storage tank (SA). 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da se taloženje kalcijevog sulfata u tekućem strujanju koje se dovodi u jedinicu za pročišćavanje dimnih plinova kontrolira smanjivanjem brzine protoka navedene frakcije tekućeg efluenta koji dolazi iz jedinice za obradu otpada (TSD) u spomenuti spremnik (SA).
The method according to any one of the previous claims, wherein said chemical-physical parameters comprise temperature, pH at 25°C, M-alkalinity, concentration of calcium, magnesium, sulphate and chloride ions, the ionic balance being closed by the concentration of sodium ion. 
Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da navedeni kemijsko-fizički parametri obuhvaćaju temperaturu, pH na 25°C, M-lužnatost, koncentraciju kalcija, magnezija, sulfatnih i kloridnih iona, a ionska ravnoteža zatvara se koncentracijom natrij iona.
The isolated rhLAL of any one of claims 1 to 6, wherein the rhLAL has a serum half-life (t1/2) that is less than 40 minutes. 
Rekombinantna humana LAL za uporabu prema zahtjevu 1, naznačena time, da spomenuta primjena, koja je dovoljna za postizanje polu-života (t1/2) za LAL, traje manje od 20 minuta.
is H, (C1-C4)-alkyl or CH(R11)COR12; or R4 and R5 taken together with the nitrogen atom to which they are attached form a three to seven membered heterocycle optionally containing a further heteroatom selected from the group consisting of N, O or S; and wherein said heterocycle is optionally substituted once or more by OH, OMe, (C1-C4)-alkyl, optionally substituted phenyl, or benzyl; 
je H, (C1-C4)-alkil ili CH(R11)COR12; ili i R5 uzeti zajedno sa atomom dušika za koji su vezani formiraju tro- do sedmo-člani heterociklus koji izborno sadrži dodatni heteroatom izabran iz grupe koju čine N, O ili S; i gdje je navedeni heterociklus izborno supstituiran jednom ili više puta sa OH, OMe, (C1-C4)-alkilom, izborno supstituiranim fenilom ili benzilom;
is a side chain of a natural a-amino acid; 
je bočni lanac prirodne a-aminokiseline;
The compound according to claim 4, wherein the medicament is useful for treating a pathological state for which the modulation of Hsp90 activity would result at improving the health of the patient. 
Spoj prema patentnom zahtjevu 4, gdje je lijek koristan za tretman patološkog stanja za koje bi modulacija aktivnosti Hsp90 rezultirala u poboljšanju zdravlja pacijenta.
The compound according to claim 6 where the neurodegenerative disease is Parkinson disease, Huntington disease, Alzheimer disease, dementia with Lewy bodies, amyotrophic lateral sclerosis, spinal and bulbar muscular atrophy or spinocerebellar ataxia. 
Spoj prema patentnom zahtjevu 6, pri čemu, neurodegenerativna bolest je Parkinsonova bolest, Hantingtonova bolest, Alzheimerova bolest, demencija sa Luisovim tijelima, amiotrofna lateralna skleroza, spinalna i bulbarna muskularna atrofija ili spinocerebelarna ataksija.
The compound according to claim 6 where the cancer disease is a cancer of the breasts, pancreas, lung, pleura, colon, peritoneum, skin, face and neck, kidney, bladder, brain, prostate, cervix, ovaries, eyes or the cancer disease is a leukaemia or is a metastatic cancer. 
Spoj prema patentnom zahtjevu 6, pri čemu, bolest kancer je kancer dojke, pankreasa, pluća, pleure, debelog crijeva, peritoneuma, kože, lica i vrata, bubrega, bešike, mozga, prostate, grlića materice, jajnika, očiju i bolest kancer je leukemija ili metastatski kancer.